Hepion Pharmaceuticals, Inc. (CTRVP) Free cash flow 2016–2024
Hepion Pharmaceuticals, Inc. (CTRVP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$18.2MFY2024 · since FY2016: -$19.2M → -$18.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$18.2M | +55.4% |
| FY2023 | -$40.9M | -16.6% |
| FY2022 | -$35.1M | -12.1% |
| FY2021 | -$31.3M | -93.1% |
| FY2020 | -$16.2M | — |
| FY2016 | -$19.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTRVP financial trends
CTRVP RevenueCTRVP Net incomeCTRVP Net marginCTRVP Gross profitCTRVP Gross marginCTRVP Operating incomeCTRVP Operating marginCTRVP Operating cash flowCTRVP Capital expendituresCTRVP Return on equityCTRVP Stock buybacksCTRVP Dividends paidCTRVP Total assetsCTRVP Total liabilitiesCTRVP Shareholders’ equityCTRVP overview →